Edition:
India

Aptinyx Inc (APTX.OQ)

APTX.OQ on NASDAQ Stock Exchange Global Select Market

21.06USD
9:48pm IST
Change (% chg)

$-0.13 (-0.61%)
Prev Close
$21.19
Open
$21.51
Day's High
$21.91
Day's Low
$20.86
Volume
8,221
Avg. Vol
36,181
52-wk High
$32.25
52-wk Low
$17.35

Latest Key Developments (Source: Significant Developments)

Aptinyx Reports Positive Data From Interim Analysis Of Exploratory Study Of NYX-2925 In Subjects With Fibromyalgia
Monday, 3 Dec 2018 

Dec 3 (Reuters) - Aptinyx Inc ::APTINYX REPORTS POSITIVE DATA FROM INTERIM ANALYSIS OF EXPLORATORY STUDY OF NYX-2925 IN SUBJECTS WITH FIBROMYALGIA.APTINYX INC - OBSERVED CORRESPONDING TRENDS OF IMPROVEMENT ON MULTIPLE SECONDARY ENDPOINTS.APTINYX INC - NYX-2925 WAS WELL TOLERATED WITH NO SUBJECTS REPORTING TREATMENT-RELATED SERIOUS ADVERSE EVENTS.APTINYX INC - NYX-2925 STUDY IS ONGOING WITH FULL DATA EXPECTED TO READ OUT IN FIRST HALF OF 2019.APTINYX INC - EXPECTS TO INITIATE A LARGER PHASE 2 STUDY OF NYX-2925 IN SUBJECTS WITH FIBROMYALGIA IN 2019.APTINYX INC - ACHIEVED STATISTICAL SIGNIFICANCE ON PRIMARY IMAGING-BASED ENDPOINT, CHANGES IN MARKERS OF CENTRAL PAIN PROCESSING, IN 11 SUBJECTS.  Full Article

Aptinyx Q3 Loss Per Share $0.43
Tuesday, 13 Nov 2018 

Nov 13 (Reuters) - Aptinyx Inc ::APTINYX REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS AND BUSINESS HIGHLIGHTS.Q3 LOSS PER SHARE $0.43.Q3 EARNINGS PER SHARE VIEW $-1.01 -- THOMSON REUTERS I/B/E/S.PLANS TO ANNOUNCE DATA FROM INTERIM ANALYSIS OF EXPLORATORY FIBROMYALGIA STUDY IN DECEMBER 2018.  Full Article

Aptinyx Completes Enrollment In Phase 2 Study Of Nyx-2925 For Painful Diabetic Peripheral Neuropathy
Thursday, 1 Nov 2018 

Nov 1 (Reuters) - Aptinyx Inc ::APTINYX COMPLETES ENROLLMENT IN PHASE 2 STUDY OF NYX-2925 FOR PAINFUL DIABETIC PERIPHERAL NEUROPATHY.APTINYX INC - TOP-LINE DATA EXPECTED EARLY IN Q1 OF 2019.APTINYX INC - STUDY IS A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY.  Full Article

Frazier Life Sciences VIII LP Reports 9.5 Pct Stake In Aptinyx Inc
Thursday, 5 Jul 2018 

July 5 (Reuters) - Aptinyx Inc ::FRAZIER LIFE SCIENCES VIII LP SAYS REPORTS 9.5 PERCENT STAKE IN APTINYX INC AS OF JUNE 25 - SEC FILING.FRAZIER LIFE SCIENCES VIII LP SAYS ACQUIRED APTINYX INC SHARES FOR INVESTMENT PURPOSES.  Full Article

Bain Capital Life Sciences Fund LP Reports A 6.2 Pct Stake In Aptinyx As Of June 25
Wednesday, 4 Jul 2018 

July 3 (Reuters) - Aptinyx Inc ::BAIN CAPITAL LIFE SCIENCES FUND LP REPORTS A 6.2 PCT STAKE IN APTINYX AS OF JUNE 25 - SEC FILING.  Full Article

New Leaf Ventures III Lp Reports 8.7 Percent Stake In Aptinyx Inc As Of June 25 - SEC Filing
Wednesday, 4 Jul 2018 

July 3 (Reuters) - Aptinyx Inc ::NEW LEAF VENTURES III LP REPORTS 8.7 PERCENT STAKE IN APTINYX INC AS OF JUNE 25 - SEC FILING.NEW LEAF VENTURES III LP SAYS ACQUIRED AN INTEREST IN APTINYX INC FOR INVESTMENT PURPOSES.  Full Article

Longitude Capital Partners II Reports A 9.5 Pct Stake In Aptinyx As Of June 25
Tuesday, 3 Jul 2018 

July 2 (Reuters) - Aptinyx Inc ::LONGITUDE CAPITAL PARTNERS II LLC REPORTS A 9.5 PCT STAKE IN APTINYX INC <<>> AS OF JUNE 25 - SEC FILING.  Full Article

Aptinyx Shares Debut At $17.40, About 8.8 Pct Above IPO Price
Thursday, 21 Jun 2018 

June 21 (Reuters) - Aptinyx Inc ::APTINYX SHARES DEBUT AT $17.4 ON THE NASDAQ VERSUS IPO PRICE OF $16/SHARE.  Full Article

Aptinyx Announces Pricing Of Initial Public Offering
Thursday, 21 Jun 2018 

June 20 (Reuters) - Aptinyx Inc ::APTINYX ANNOUNCES PRICING OF INITIAL PUBLIC OFFERING.SAYS INITIAL PUBLIC OFFERING OF 6.40 MILLION COMMON SHARES PRICED AT $16.00PER SHARE.  Full Article